Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
TECN Stock Overview
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories.
Tecan Group Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF287.60 |
52 Week High | CHF602.00 |
52 Week Low | CHF264.60 |
Beta | 0.39 |
1 Month Change | -8.47% |
3 Month Change | -23.18% |
1 Year Change | -40.06% |
3 Year Change | 11.99% |
5 Year Change | 60.31% |
Change since IPO | 513.22% |
Recent News & Updates
Should You Be Adding Tecan Group (VTX:TECN) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Shareholder Returns
TECN | CH Life Sciences | CH Market | |
---|---|---|---|
7D | 6.4% | 4.9% | 3.8% |
1Y | -40.1% | -25.2% | -11.8% |
Return vs Industry: TECN underperformed the Swiss Life Sciences industry which returned -24.7% over the past year.
Return vs Market: TECN underperformed the Swiss Market which returned -12.4% over the past year.
Price Volatility
TECN volatility | |
---|---|
TECN Average Weekly Movement | 6.5% |
Life Sciences Industry Average Movement | 6.5% |
Market Average Movement | 4.6% |
10% most volatile stocks in CH Market | 7.6% |
10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: TECN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TECN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | 3,291 | Achim von Leoprechting | https://www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions.
Tecan Group Fundamentals Summary
TECN fundamental statistics | |
---|---|
Market Cap | CHF3.66b |
Earnings (TTM) | CHF121.66m |
Revenue (TTM) | CHF946.62m |
30.1x
P/E Ratio3.9x
P/S RatioIs TECN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TECN income statement (TTM) | |
---|---|
Revenue | CHF946.62m |
Cost of Revenue | CHF538.05m |
Gross Profit | CHF408.57m |
Other Expenses | CHF286.91m |
Earnings | CHF121.66m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 17, 2022
Earnings per share (EPS) | 9.56 |
Gross Margin | 43.16% |
Net Profit Margin | 12.85% |
Debt/Equity Ratio | 20.4% |
How did TECN perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield28%
Payout RatioValuation
Is TECN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TECN?
Other financial metrics that can be useful for relative valuation.
What is TECN's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | CHF3.66b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.9x |
Enterprise Value/EBITDA | 20.3x |
PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does TECN's PE Ratio compare to its peers?
TECN PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 59x | ||
BANB Bachem Holding | 47.2x | 16.5% | CHF5.4b |
SFZN Siegfried Holding | 28.3x | 12.1% | CHF2.7b |
PPGN PolyPeptide Group | 47.6x | 15.3% | CHF2.3b |
SKAN SKAN Group | 112.7x | 24.1% | CHF1.2b |
TECN Tecan Group | 30.1x | 13.0% | CHF3.7b |
Price-To-Earnings vs Peers: TECN is good value based on its Price-To-Earnings Ratio (30.1x) compared to the peer average (59x).
Price to Earnings Ratio vs Industry
How does TECN's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: TECN is good value based on its Price-To-Earnings Ratio (30.1x) compared to the Swiss Life Sciences industry average (46.2x)
Price to Earnings Ratio vs Fair Ratio
What is TECN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 30.1x |
Fair PE Ratio | 35.3x |
Price-To-Earnings vs Fair Ratio: TECN is good value based on its Price-To-Earnings Ratio (30.1x) compared to the estimated Fair Price-To-Earnings Ratio (35.3x).
Share Price vs Fair Value
What is the Fair Price of TECN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TECN (CHF287.6) is trading below our estimate of fair value (CHF487.74)
Significantly Below Fair Value: TECN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: TECN is poor value based on its PEG Ratio (2.3x)
Discover undervalued companies
Future Growth
How is Tecan Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
13.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECN's forecast earnings growth (13% per year) is above the savings rate (-0.3%).
Earnings vs Market: TECN's earnings (13% per year) are forecast to grow faster than the Swiss market (6.1% per year).
High Growth Earnings: TECN's earnings are forecast to grow, but not significantly.
Revenue vs Market: TECN's revenue (8% per year) is forecast to grow faster than the Swiss market (4.2% per year).
High Growth Revenue: TECN's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TECN's Return on Equity is forecast to be low in 3 years time (12.4%).
Discover growth companies
Past Performance
How has Tecan Group performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
19.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TECN has high quality earnings.
Growing Profit Margin: TECN's current net profit margins (12.9%) are lower than last year (14.2%).
Past Earnings Growth Analysis
Earnings Trend: TECN's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: TECN's earnings growth over the past year (17.3%) is below its 5-year average (19% per year).
Earnings vs Industry: TECN earnings growth over the past year (17.3%) underperformed the Life Sciences industry 50.8%.
Return on Equity
High ROE: TECN's Return on Equity (9.9%) is considered low.
Discover strong past performing companies
Financial Health
How is Tecan Group's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: TECN's short term assets (CHF671.9M) exceed its short term liabilities (CHF306.4M).
Long Term Liabilities: TECN's short term assets (CHF671.9M) exceed its long term liabilities (CHF464.9M).
Debt to Equity History and Analysis
Debt Level: TECN's net debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: TECN's debt to equity ratio has increased from 0.6% to 20.4% over the past 5 years.
Debt Coverage: TECN's debt is well covered by operating cash flow (67.9%).
Interest Coverage: TECN's interest payments on its debt are well covered by EBIT (35.9x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Tecan Group current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.97%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TECN's dividend (0.97%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.99%).
High Dividend: TECN's dividend (0.97%) is low compared to the top 25% of dividend payers in the Swiss market (4.14%).
Stability and Growth of Payments
Stable Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: TECN is not paying a notable dividend for the Swiss market.
Cash Payout to Shareholders
Cash Flow Coverage: TECN is not paying a notable dividend for the Swiss market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.0yrs
Average management tenure
CEO
Achim von Leoprechting (53 yo)
9.42yrs
Tenure
CHF3,141,000
Compensation
Dr. Achim Von Leoprechting, Ph D., has been Chief Executive Officer of Tecan Group Ltd., since April 1, 2019. He had been Head of the Partnering Business division at Tecan Group Ltd.since October 1, 2013...
CEO Compensation Analysis
Compensation vs Market: Achim's total compensation ($USD3.29M) is above average for companies of similar size in the Swiss market ($USD1.84M).
Compensation vs Earnings: Achim's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: TECN's management team is seasoned and experienced (6 years average tenure).
Board Members
Experienced Board: TECN's board of directors are considered experienced (9.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
Top Shareholders
Company Information
Tecan Group AG's employee growth, exchange listings and data sources
Key Information
- Name: Tecan Group AG
- Ticker: TECN
- Exchange: SWX
- Founded: 1980
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF3.659b
- Shares outstanding: 12.72m
- Website: https://www.tecan.com
Number of Employees
Location
- Tecan Group AG
- Seestrasse 103
- Männedorf
- Zurich
- 8708
- Switzerland
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/27 00:00 |
End of Day Share Price | 2022/06/27 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.